This market research study presents a detailed segmentation of the global postmenopausal osteoporosis drugs market by therapeutic class (antiresorptive medications and anabolic medications), by line of therapy (first line of therapy and second line of therapy), and by geography (the Americas, APAC, and EMEA). Leading vendors in this market are Eli Lilly, Amgen, Merck, and Novartis.
The market research analysts at Technavio estimate the postmenopausal osteoporosis drug market to grow at a CAGR of over 4% between 2016 and 2020. The pervasiveness of osteoporosis and increase in the older women population are the primary drivers for this market. Factors such as high unmet needs and the launch of new drugs are expected to propel the postmenopausal osteoporosis drugs market globally during the forecast period. At present, the Americas dominate the market by accounting for over 46% of the overall market share. The approval of a novel class of drugs such as Pfizer’s Duavee and Amgen’s Prolia are expected to propel the market in this region during the forecast period.
The new market research report from Technavio presents a breakdown and analysis of the postmenopausal osteoporosis market segments by line of therapy.
“Promotion of bone health awareness among patients and physicians is the latest trend that is catching up in the market. Various governmental and non-governmental organizations are launching awareness programs to promote the understanding of the disease along with taking the necessary preventive measures. For instance, National Women’s Health Week is organized by the Health and Human Services (HHS) in May to increase awareness about women’s health,” says Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
In 2015, the first line of therapy dominated the postmenopausal osteoporosis drugs market across the globe by accounting for over 64% of the overall market share. Optimal consumption of Vitamin D is the most acclaimed baseline therapy to prevent and treat osteoporosis. The first-line preventive therapy in postmenopausal women with low bone density and glucocorticoid-induced osteoporosis include bisphosphonates such as alendronate, etidronate, risedronate, and zoledronic acid.
The key vendors in the global postmenopausal osteoporosis drugs market include Eli Lilly, Amgen, Merck, and Novartis. The global postmenopausal osteoporosis drugs market is highly competitive due to the presence of several international and regional vendors. The market is open to new players and has a lot of opportunities for growth. The competitive environment is expected to increase due to the product extensions, new products, and new applications of the products and services provided.
A more detailed analysis is available on the Technavio report, Global Postmenopausal Osteoporosis Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
